Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sanwa Kagaku Licenses SK-0403 to ChoongWae in South Korea
September 8, 2008
- Vascular Embolization Set for AVM Recommended for Approval
September 8, 2008
- Shionogi to Directly Enter US Market by Acquiring Sciele Pharma
September 8, 2008
- R&D NEWS IN BRIEF
September 8, 2008
- Astellas Aims at Top Market Share in Japan
September 8, 2008
- 4 Healthcare Clusters to Focus on 4 Fields
September 8, 2008
- Prevent Recurrence of Stroke: Prof. Hasegawa
September 8, 2008
- Recommending Hp Eradication in All Infected Persons: JSHR
September 8, 2008
- Takara Bio to Start Cancer Cell Immunotherapy in Kyoto Clinic
September 8, 2008
- Takeda Suspends Development of Hematide for Chemotherapy-Induced Cancerous Anemia
September 8, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 8, 2008
- CGI to Stop PIII Trial on Prostate Cancer Vaccine Licensed to Takeda
September 8, 2008
- METI Demands \609.3 Bil. to Promote Science & Technology
September 8, 2008
- PM Yasuo Fukuda Steps Down
September 8, 2008
- Korosho to Demand \33.2 Bil. to Develop Drugs, Med. Devices
September 8, 2008
- Committee Recommends Approval of Generic Vancomycin from Mylan
September 8, 2008
- Draft Nat'l Medical Expenditure Optimization Plan Announced
September 8, 2008
- Thalidomide Safety Control Criteria Discussed by Study Group
September 8, 2008
- Prasugrel Inhibits Recurrence of CV Events More Effectively than Clopidogrel
September 1, 2008
- REGULATORY NEWS IN BRIEF
September 1, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…